Rockefeller Capital Management
SPRY icon

Rockefeller Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Rockefeller Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.8K Buy
5,454
+3,560
+188% +$34.1K ﹤0.01% 3349
2025
Q4 		$22.1K Buy
1,894
+894
+89% +$8.69K ﹤0.01% 3469
2025
Q3 		$10.1K Buy
+1,000
New +$14.4K ﹤0.01% 3643

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Rockefeller Capital Management's SPRY Position: Q1 2026 in Review

Rockefeller Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 188% in Q1 2026, buying an estimated $34.1K and bringing the position to 5,454 shares worth $43.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3349.

Rockefeller Capital Management first reported a position in SPRY in Q3 2025 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Rockefeller Capital Management held 5,454 shares of ARS Pharmaceuticals worth $43.8K as of Q1 2026.
  • Rockefeller Capital Management bought 3,560 ARS Pharmaceuticals shares in Q1 2026, an estimated $34.1K.
  • ARS Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3349 holding.
  • Rockefeller Capital Management first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.